China Cancer Biomarker-based Assay Market Size, Share, By Type (Genetic Biomarkers, Protein Biomarkers, Epigenetic Biomarkers, Glycan Biomarkers, and Metabolic Biomarkers), By Biomolecule (DNA, RNA, Proteins, and Other Biomolecules), By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, and Other Cancer Types), and China Cancer Biomarker-based Assay Market Insights, Industry Trend, Forecasts to 2035

China Cancer Biomarker-based Assay Market Insights Forecasts to 2035

• China Cancer Biomarker-based Assay Market Size 2024: USD 1.47 Bn
• China Cancer Biomarker-based Assay Market Size 2035: USD 9.45 Bn
• China Cancer Biomarker-based Assay Market CAGR: 18.43%
• China Cancer Biomarker-based Assay Market Segments: Type, Biomolecule, and Cancer Type

Cancer biomarker–based assays are diagnostic tests that identify biological markers such as genetic mutations, proteins, and other molecular signatures. Precision oncology and personalized medicine approaches rely on these assays for early detection, prognosis, therapy selection, and treatment response monitoring. Next-generation sequencing (NGS), PCR, immunoassays, and liquid biopsy tests are examples of biomarker assays that enable precise and sensitive cancer profiling. The rising incidence of cancer, increasing awareness of early diagnosis, and China’s expanding molecular diagnostics infrastructure are the key drivers of market growth.

Market Dynamics of the China Cancer Biomarker-Based Assay Market

The cancer biomarker-based assay market in China is expanding rapidly due to the rising prevalence of cancer and the increasing focus on early and accurate diagnosis. Demand for biomarker assays that enable early detection, prognosis, and personalized treatment planning is growing as cancer rates increase due to environmental factors, lifestyle changes, and demographic shifts. The expansion of cancer screening programs and supportive government health policies further encourages the adoption of advanced diagnostic technologies in hospitals and oncology centers. Additionally, China’s push toward precision medicine supported by investments in genomics and molecular diagnostics infrastructure—is accelerating the integration of biomarker assays into clinical workflows.

Despite strong growth prospects, several challenges may slow adoption. Advanced biomarker tests and sophisticated diagnostic equipment remain expensive, particularly in low-income and rural regions with limited healthcare resources. Regulatory hurdles and lengthy approval processes may also delay the commercialization and market launch of innovative biomarker assays. Moreover, regional disparities in the implementation of standardized screening protocols lead to unequal access to diagnostic services, limiting the broader adoption of biomarker-based assays.

Nevertheless, significant opportunities exist. The growing emphasis on noninvasive cancer screening methods, liquid biopsy technologies, and precision oncology is creating avenues for innovation and new product development. The expansion of China’s clinical trial networks and international collaborations with research organizations is accelerating the discovery and validation of novel biomarkers tailored to the Chinese population. Furthermore, rising demand for personalized cancer therapies, along with government initiatives aimed at strengthening diagnostic infrastructure and early detection programs, is expected to support sustained long-term market growth.

Market Segmentation

The China cancer biomarker-based assay market is segmented by type, biomolecule, and cancer type.

By Type

Based on type, the market is categorized into genetic biomarkers, protein biomarkers, epigenetic biomarkers, glycan biomarkers, and metabolic biomarkers. Among these, the genetic biomarkers segment held the largest market share in 2024 and is projected to grow at a remarkable rate during the forecast period. Genetic biomarkers are widely used due to their high sensitivity and specificity in early cancer detection, enabling accurate diagnosis and personalized treatment planning.

By Biomolecule

Based on biomolecule, the market is divided into DNA, RNA, proteins, and other biomolecules. Among these, the DNA segment accounted for the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The dominance of DNA-based assays is attributed to their high accuracy and reliability in detecting genetic mutations and cancer-related alterations, which are critical for early diagnosis and targeted therapy. Advances in next-generation sequencing (NGS) and PCR technologies have further enhanced the sensitivity and scalability of DNA assays, driving their widespread adoption in clinical and research settings.

By Cancer Type

By cancer type, the market is segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, and other cancer types. Among these, the lung cancer segment dominated the market in 2024 and is anticipated to grow at a notable CAGR during the forecast period. Lung cancer remains one of the most prevalent and deadly cancers in China, making early detection and accurate diagnosis essential. Biomarker-based assays for lung cancer support early-stage detection, personalized treatment planning, and therapy monitoring, all of which are crucial for improving patient outcomes.

Competitive Analysis

The report provides a comprehensive analysis of the key companies operating in the China cancer biomarker-based assay market, along with a comparative evaluation based on their product portfolios, business overviews, geographic presence, strategic initiatives, segmental market share, and SWOT analysis. It also includes an in-depth review of recent developments such as product launches, technological innovations, joint ventures, partnerships, mergers and acquisitions, and strategic alliances. This analysis helps assess the overall competitive landscape of the market.

Top Key Companies in the China Cancer Biomarker-based Assay Market:

• Illumina, Inc.
• Bio-Rad Laboratories, Inc.
• BGI Genomics Co., Ltd.
• Burning Rock Dx Co., Ltd.
• Berry Genomics Co., Ltd.
• Novogene Co., Ltd.
• Foundation Medicine, Inc.
• Myriad Genetics, Inc.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at the China, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the China cancer biomarker-based assay market based on the following segments:

China Cancer Biomarker-based Assay Market, By Type

• Genetic Biomarkers
• Protein Biomarkers
• Epigenetic Biomarkers
• Glycan Biomarkers
• Metabolic Biomarkers

China Cancer Biomarker-based Assay Market, By Biomolecule

• DNA
• RNA
• Proteins
• Other Biomolecules

China Cancer Biomarker-based Assay Market, By Cancer Type

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Other Cancer Types